中国肿瘤生物治疗杂志2025，Vol.32Issue(1)：9-13,5.DOI:10.3872/j.issn.1007-385x.2025.01.002
CAR-T细胞治疗的临床关键问题和对策
Clinical key issues and countermeasures of CAR-T cell therapy
摘要
Abstract
Since 2017,twelve chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell)products have been approved for the treatment of hematological malignancies,including relapsed/refractory acute B lymphoblastic leukemia(B-ALL),specific subtypes of B cell lymphoma,and multiple myeloma.However,CAR-T cell therapy faces numerous challenges in its clinical application,such as resistance,lengthy production cycles,high individuation and costs in hematological tumors,and tumor heterogeneity/antigen escape,insufficient infiltration capability,immunosuppressive microenvironments,and poor therapeutic response in solid tumors.With the in-depth exploration of tumor immunology and the development of genetic engineering technology,various new strategies have been attempted to enhance the efficacy and generalizability of CAR-T cell therapy.This paper presents a commentary on CAR-T cell therapy,with a focus on key clinical issues and corresponding countermeasures,providing valuable insights for future basic research and clinical transformation of CAR-T cell therapy.关键词
免疫治疗/嵌合抗原受体基因修饰T淋巴细胞/肿瘤微环境/实体瘤Key words
immunotherapy/chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell)/tumor microenvironment/solid tumor分类
临床医学引用本文复制引用
陈新峰,刘莎莎,张毅..CAR-T细胞治疗的临床关键问题和对策[J].中国肿瘤生物治疗杂志,2025,32(1):9-13,5.基金项目
国家自然科学基金(No.U24A20734,No.82370227) （No.U24A20734,No.82370227）
河南省中央引导地方科技发展资金项目(No.Z20221343036) （No.Z20221343036）
